Search tips
Search criteria 


J Hepatol. 2013 May; 58(5): 868–874.
PMCID: PMC3625113

γ-H2AX + CD8+ T lymphocytes cannot respond to IFN-α, IL-2 or IL-6 in chronic hepatitis C virus infection


Background & Aims

Age is the dominant prognostic factor influencing the natural history of hepatitis C virus (HCV) infection and treatment response. Accelerated lymphocyte telomere shortening in HCV infection correlates with adverse clinical outcomes. Critical telomere shortening generates double-stranded DNA breaks (DSB) inducing the DNA damage response, leading to replicative senescence. The phenotype and function of CD8+ T lymphocytes and the in vitro response to IFN-α in relation to the DNA damage response were investigated in patients with chronic HCV infection.


CD8+ T lymphocytes with DSB were identified by expression of γ-H2AX (Ser-139) in 134 HCV-exposed subjects and 27 controls. Telomere length was determined by flow-FISH; cytokine expression by intracellular cytokine staining; in vitro responses to IFN-α, IL-2 or IL-6 by phospho-STAT1 (Y701) or phospho-STAT5 (Y694) expression.


The proportion of circulating CD8 + γ-H2AX+ T lymphocytes rose with increasing fibrosis stage (p = 0.0023). CD8 + γ-H2AX+ T lymphocytes were enriched in liver compared to blood (p = 0.03). CD8 + γ-H2AX+ T lymphocytes demonstrated increased IFN-γ (p = 0.02) and reduced IL-2 expression (p = 0.02). CD8 + γ-H2AX+ T lymphocytes failed to phosphorylate STAT1 in response to IFN-α compared to unfractionated CD8+ T lymphocytes (p <0.0001). More widespread failure of Jak/Stat signalling in CD8 + γ-H2AX+ T lymphocytes was suggested by impaired phosphorylation of STAT1 with IL-6 (p = 0.002) and STAT5 with IL-2 (p = 0.0039) compared to unfractionated CD8+ T-lymphocytes.


In chronic HCV infection, CD8 + γ-H2AX+ T lymphocytes are highly differentiated with shortened telomeres, are more frequent within the liver, are associated with severe fibrosis and fail to activate Jak/Stat pathways in response to IFN-α, IL-2 or IL-6, perhaps explaining treatment failure in those with severe fibrosis.

Abbreviations: HCV, Hepatitis C virus; DSB, double-stranded DNA breaks; ATM, ataxia telangiectasia-mutated; IFN-α, interferon-α; PBMC, peripheral blood mononuclear cells; DDR, DNA damage response; SOCS, suppressor of cytokine signalling
Keywords: Hepatitis C, T-lymphocytes, Senescence, Interferon-alpha, γ-H2AX


Several factors influence the risk of progressive liver injury in chronic hepatitis C virus (HCV) infection, including male sex and alcohol misuse [1], but increasing age has perhaps the strongest association with progressive fibrosis and treatment failure [2–4].

Healthy aging is associated with shortened telomeres in lymphoid and non-lymphoid cells [5,6]. Short telomeres are detected by the MRN protein complex including MRE11, NBS1 and RAD50 [7,8], leading to recruitment of ataxia telangiectasia-mutated (ATM) and ataxia telangiectasia and Rad3 related (ATR) serine/threonine kinases [8,9]. A number of nuclear targets are phosphorylated subsequently, including Histone 2 at serine 139 to form γ-H2AX [10,11]. γ-H2AX recruits further ATM complexes to the site of its formation in a positive feedback loop and also initiates stabilisation of p53 and its downstream target p21, leading ultimately to cell-cycle arrest [10,12].

Cellular responses to interferon-α (IFN-α) are important following exposure to HCV and during anti-viral therapy. IFN-α binds to IFN-AR2, which forms a heterodimer with IFN-AR1, triggering an intracellular signalling cascade through the Jak/Stat pathway [13]. Phosphorylation of Jak1 and Tyk2 associated with the intracellular tail of IFN-AR1 leads to phosphorylation of STAT1 at tyrosine 701. Treatment outcome in HCV infected patients is related closely to the transcriptome generated in response to IFN-α [14–16].

HCV modulates cellular responses to endogenous IFN-α signalling through pSTAT1. HCV core prevents phosphorylation of STAT1 in response to IFN-α [17] and NS5A prevents translocation of pSTAT1 to the nucleus [18]. Shorter telomeres are associated with defective activation of STAT5 in mouse macrophages [19].

In a previous study in chronic HCV infection progressive fibrosis, an adverse clinical outcome and impaired treatment responses were each associated with shortened CD8+ and CD4+ T-lymphocyte telomeres [20]. We therefore investigated the in vitro response to IFN-α in CD8+ T cells in relation to shortened telomeres and γ-H2AX expression as a measure of double strand DNA break signalling.

Materials and methods

Subjects (Table 1)

Table 1
Demographic data of subjects in the four study groups.

Patients recruited at Addenbrooke’s Hospital, Cambridge gave written informed consent with approval of the Local Research Ethics Committee. Patients co-infected with HIV, HBV or with other chronic liver diseases, identified by history, blood tests or liver biopsy, were excluded. Lymphocytes from healthy controls were obtained from local volunteers; none gave a history of chronic illness or intravenous drug usage. Liver biopsies were scored according to Ishak criteria by a specialist liver histopathologist (SED). Fibrosis was staged 0 (absent)–6 (cirrhosis); mild liver disease was defined as a fibrosis score of 0–3 and severe 4–6.

Viral serology and PCR

Routine serology and PCR were performed in the Department of Virology, Addenbrooke’s Hospital, Cambridge as described previously [20].

Lymphocyte preparation, culture and T-cell receptor directed stimulation

Peripheral blood mononuclear cells (PBMCs) were obtained by centrifugation of citrated blood over Lymphoprep (Nycomed). Cells were cultured in RPMI-1640 medium supplemented with 2 mM l-glutamine, 10% foetal calf serum (Biosera), 100 IU/ml penicillin and 0.1 mg/ml streptomycin (Sigma–Aldrich).

Cells were cultured with or without variable concentrations of interferon-α2b (PBL biomedical laboratories), IL-2 or IL-6 (Roche Applied Sciences).

Control (unstimulated) PBMC or PBMC stimulated with 1 μg/ml plate-bound anti-CD3 and 4 μg/ml soluble anti-CD28 (BD) were incubated in a humidified 5% CO2 atmosphere for 15 h. After 2 h, Brefeldin A (BD) was added according to the manufacturer’s instructions.

Flow cytometry

All cytometry was performed on a FACSCanto II analyser (BD); data were analysed with FACSDiva software (BD).

PBMCs were stained for cell surface markers before fixation in CALTAG medium A. Cells were permeabilised in ice-cold 90% methanol (VWR) and then stained with combinations of Alexa Fluor (AF) 488 or AF647 conjugated anti-γ-H2AX (Ser-139) (Cell Signaling) or other intracellular antigens or appropriate isotype controls. For further details of antibodies see Supplementary Materials and methods.

A positive control for γ-H2AX (PBMCs irradiated with 50 Gy) was included in every run. Streptavidin-Cy3 (Cedarlane Labs) was utilised with biotinylated primary antibodies. Class 1 pentamer analysis was performed in HLA-A2 positive individuals utilising HCV NS3 (KLVALGINAV) or CMV pp65 (NLVPMVATV) according to the manufacturer’s instructions (Proimmune).

Telomere length by flow cytometry

Telomere length of CD8+ T cells was measured using flow-FISH assay [20]. CD4+ PBMCs from one healthy individual were analysed in every experiment as an internal control. Lymphocyte telomere length within an individual was expressed as mean fluorescence intensity (MFI). CD8+ lymphocytes were negatively selected using the CD8+ isolation kit II (Miltenyi Biotec) prior to staining and in situ hybridisation. CD8+ purity always exceeded 90%.


Data are the median (interquartile range), unless stated otherwise. γ-H2AX expression in different patient groups and cell surface phenotype of γ-H2AX+ cells were analysed by Kruskal–Wallis test. Paired data from unfractionated CD8+ and γ-H2AX + CD8+ T cells were analysed by Wilcoxon signed rank test. Absolute pSTAT1 responses and p53 expression were analysed by 2-way ANOVA. Dose–response curves and EC50 were calculated by Prism 5.0 (Graphpad Software). The correlation between γ-H2AX expression and telomere length, age or BMI was analysed by Spearman’s rank correlation.

Multiple linear regression analysis was performed to identify predictors of γ-H2AX expression using SPSS 15.0. Only variables with a p value of <0.10 on univariate analysis were subjected to multivariate analysis. p values of <0.05 were considered significant.


Flow-cytometry was used to detect γ-H2AX, a marker of DNA double-strand breaks, to investigate the relation between peripheral CD8+ T-lymphocyte telomere length and downstream signalling (Fig. 1A). Subjects with CD8 + CD45RO+ T lymphocytes with shortened telomeres had an increased proportion of circulating γ-H2AX + CD8+ T lymphocytes (= 0.006, Rs = −0.23, Fig. 1B). The proportion of circulating γ-H2AX + CD8+ T lymphocytes in HCV-RNA+ patients with severe fibrosis (median 2.8% (1.5–4.6)) was higher than in healthy controls (1.8% (0.98–2.4)), HCV-RNA-negative HCV-exposed subjects (2.0% (1.1–3.5)) and HCV-RNA-positive patients with mild fibrosis (1.4% (0.8–2.4), Kruskal Wallis = 0.0023, Fig. 1C).

Fig. 1
γ-H2AX (Ser-139) expression on circulating CD8+ T lymphocytes in healthy controls and HCV-infected subjects. (A) Gating strategy for γ-H2AX; cells within the live lymphocyte gate by scatter characteristics (left panel) and positive staining ...

To study the independent association between clinical and demographic factors with CD8+ T-lymphocyte γ-H2AX expression in HCV-RNA+ subjects (n = 109), a multiple linear regression model was constructed (Supplementary Fig. 1 and Table 2). By univariate analysis, increased fibrosis stage (p <0.001) and a low ALT (= 0.059) were associated with increased γ-H2AX expression. On multivariate analysis, increased fibrosis stage (p <0.001) and low ALT (= 0.025) were independently associated with increased γ-H2AX expression (Table 2).

Table 2
Clinical and demographic factors associated with γ-H2AX expression on CD8+ T lymphocytes from HCV-RNA+ subjects (n = 109) by multiple linear regression.

There was increased γ-H2AX expression on CD8+ T lymphocytes in subjects with past exposure to CMV (Supplementary Fig. 1G–I), which is probably explained by a higher proportion of CD8+ T lymphocytes with an advanced cell surface phenotype, defined by CD27 and CD57 expression and described previously in CMV [21] (Supplementary Fig. 1H). There was no increase in γ-H2AX expression when the analysis was restricted to the CD27- subset, controlling for this increase in highly differentiated cells (Supplementary Fig. 1I).

γ-H2AX expression was associated with evidence of downstream DNA damage response (DDR) signalling, as γ-H2AX + CD8+ T lymphocytes had increased phosphorylation of p53 at serine 15 (Fig. 1D). There was no difference in Ki67 expression between unfractionated CD8+ T lymphocytes (0.7%; 0.57–1.15) and γ-H2AX + CD8+ T lymphocytes (1.3%; 0.45–1.75, = 0.24, Fig. 1E and F), indicating γ-H2AX expression was unrelated to DNA replication.

γ-H2AX was present in a higher proportion of CD8+ T lymphocytes expressing the mature phenotypes CD27-CD57- (3.1% (1.4–5.6)) or CD27-CD57+ (3.2% (1.7–6.2)) than the less mature CD27 + CD57- subset (0.8% (0.4–1.6), p <0.0001, Fig. 1G). Consistent with this observation, CD8 + CD27- T lymphocytes had shorter telomeres (117 (111 – 134)) than CD8 + CD27+ T lymphocytes (146 (139–161), = 0.0003, Fig. 1H). Immunoblotting revealed increased γ-H2AX expression in CD8 + CD27- T lymphocytes compared to CD8+ CD27+ T lymphocytes (Fig. 1I).

Without stimulation, a higher proportion of γ-H2AX + CD8+ T lymphocytes expressed IFN-γ (3.9% (2.48–13.5)) compared with unfractionated CD8+ T lymphocytes (0.4% (0.08–1.2), = 0.002, Fig. 2A). Following overnight stimulation (with anti-CD3 and anti-CD28), a higher proportion of γ-H2AX + CD8+ T lymphocytes expressed IFN-γ (20.0% (7.8–26.9) compared with 9.6% (4.9–18.1), = 0.02) than unfractionated CD8+ T lymphocytes (Fig. 2C). However, the proportion of unstimulated γ-H2AX + CD8+ T cells expressing IL-2 was lower than unfractionated CD8+ T lymphocytes (1.8% (0–3.1) compared with 3.1% (2–5.3), = 0.03, Fig. 2D).

Fig. 2
Cytokine expression pattern of peripheral CD8+ T lymphocytes from 10 subjects with chronic HCV infection. Unfractionated CD8+ lymphocytes or γ-H2AX + CD8+ subsets were analysed for expression of (A and C) IFN-γ, and (B ...

We studied co-expression of γ-H2AX and markers of activation and known inhibitory receptors. γ-H2AX + CD8+ T cells were CD38 positive, but CD69 negative (Supplementary Fig. 2). Further, these cells did not express the inhibitory receptors PD-1 or Tim3 (Supplementary Fig. 2). γ-H2AX + CD8+ T cells were negative for CD161 [22] in 15 further patients with viraemic HCV infection (data not shown). To study potential antigen-specificity, circulating γ-H2AX + CD8+ T lymphocytes derived from three HLA-2 positive patients with positive CMV serology and current HCV infection (HCV-RNA+ in serum) showed no specificity for either HCV-NS3 or CMV-pp65, although unfractionated CD8+ T lymphocytes responded to both pentamers (Supplementary Fig. 3).

Induction of pSTAT1 expression was used as a measure of the response to in vitro IFN-α (Fig. 3A and B). CD8+ T lymphocytes from healthy controls responded with an EC50 of 99 IU/ml. Unfractionated CD8+ T lymphocytes from HCV-infected subjects had an increased EC50 when compared to healthy controls (308 IU/ml), which was still higher in γ-H2AX + CD8+ T lymphocytes (781 IU/ml) (Fig. 3A–C). The maximal response of unfractionated CD8+ T lymphocytes from HCV infected patients was similar to that in healthy controls (= 0.29, Fig. 3D) but the response of γ-H2AX+ T lymphocytes was impaired by comparison (p <0.0001). These defects could not be explained by total STAT1 content (Supplementary Fig. 4A and B), surface expression of IFN-AR components (Fig. 3E-G), failure to phosphorylate Tyk2 or Jak1 (Supplementary Fig. 4C and D) or IFN-α induced downregulation of IFN-AR from the cell surface of γ-H2AX + CD8+ T lymphocytes (Fig. 3H).

Fig. 3
CD8+ γ-H2AX+ lymphocytes fail to phosphorylate STAT1 after incubation with IFN-α unrelated to IFN-α receptor function. Circulating T lymphocytes were incubated with variable concentrations of IFN-α2b before staining for ...

A higher proportion of intrahepatic CD8+ T lymphocytes expressed γ-H2AX (2.15%, (1.28–3.65)) compared to circulating CD8+ T lymphocytes simultaneously isolated (0.25% (0.1–1.43), = 0.03, Fig. 4A and B). Intrahepatic γ-H2AX + CD8+ T lymphocytes had a similar phenotype to circulating T lymphocytes with low expression of CD27 (Fig. 4C). Intrahepatic γ-H2AX + CD8+ T lymphocytes also failed to phosphorylate STAT1 in response to IFN-α2b (Fig. 4D).

Fig. 4
CD8+ γ-H2AX+ T lymphocytes are more frequent within the liver of HCV-infected subjects. (A) Example plots of CD8 and γ-H2AX expression on peripheral (left panel) and intrahepatic (right panel) lymphocytes from an HCV-RNA+ subject. (B) ...

To investigate whether the defect in Jak/Stat signalling was confined to the IFN-α pathway, the response of γ-H2AX + CD8+ T lymphocytes to IL-6 was investigated, as this also signals through STAT1. The proportion of unfractionated CD8+ T lymphocytes that expressed pSTAT1 after exposure to 300 IU/ml IL-6 was higher than in γ-H2AX + CD8+ T lymphocytes (16.4% (12.3–28.4 and 3.9% (1.9–5.6), = 0.002, Fig. 2E and G) suggesting that defective STAT1 phosphorylation was not confined to IFN-α signalling.

IL-2-induced STAT5 phosphorylation was investigated to determine if there was an overall failure of Stat activation in γ-H2AX + CD8+ T-lymphocytes. After exposure to 10 IU/ml IL-2 the proportion of unfractionated CD8+ T lymphocytes that expressed pSTAT5 was higher than in γ-H2AX + CD8+ T lymphocytes (36.2% (23.6–39.5) and 2.7% (1.8–6.8), = 0.0039, Fig. 2F and H) suggesting a more widespread failure of Jak/Stat signalling in γ-H2AX + CD8+ T-lymphocytes.


γ-H2AX expression in circulating lymphocytes, induced by DSBs and indicative of DDR activation, correlated with reduced telomere length in CD8+ T cells and fibrosis stage. The correlation between fibrosis stage and the small proportion of circulating γ-H2AX-positive lymphocytes was perhaps surprising and may reflect accelerated ageing in many tissues including the liver, or a more direct, potent effect mediated through the secretory phenotype of senescent cells. γ-H2AX expression was confined to T cells with an advanced cell-surface phenotype and associated with a skewed cytokine expression profile (increased IFN-γ with reduced IL-2) consistent with previous data in CD4+ T lymphocytes in HCV infection [23]. γ-H2AX + CD8+ T lymphocytes had impaired phosphorylation of STAT1 in response to exogenous IFN-α, which was not explained by altered expression of IFN-AR2 or IFN-AR1, or there was evidence that the failure to phosphorylate Jak1 and Tyk2 was associated with the intracellular apparatus of the IFN-α receptor. γ-H2AX + CD8+ T lymphocytes are more abundant within HCV-infected liver and had similar surface phenotype and functional deficits to circulating γ-H2AX + CD8+ T-lymphocytes.

There was an unexplained mechanistic association between telomere shortening, downstream signalling and the failure of γ-H2AX positive cells to respond to IFN-α by phosphorylation of STAT1. Possible explanations include a lesion of either Jak1 or Tyk2 [24], expression of the truncated isoform of IFN-AR2 [25] or suppression of signalling through the suppressor of cytokine signalling (SOCS) family of proteins [26].

Pre-translational processing involving mRNA splicing can result in expression of a truncated isoform of IFN-AR2, which suppresses signalling through the IFN-AR complex to intracellular second messengers [25]. Murine cell lines, infected with VZV, failed to suppress viral replication when signalling through the isoform with a truncated cytoplasmic tail, in contrast to full length IFN-AR2. Human cells normally express the truncated isoform at low levels compared to the full length biologically active form [27]. However, studies have demonstrated that other chronic viral infections modulate the frequency of IFN-AR splice isoforms [27,28].

Hepatitis D virus suppresses IFN-α signalling through inhibition of Tyk2 phosphorylation, preventing STAT1 phosphorylation and activation [24]. Our data precluded a similar mechanism, but there may be a failure of kinase function of the activated intracellular tail of the IFN-α receptor.

γ-H2AX expression often reflects the cellular response to shortened telomeres, but is also generated at the site of any break in double-stranded DNA. γ-H2AX expression is related to critical telomere shortening, but that is not the only explanation [10,11,29]. In cells exposed to increased DNA damage, through oncogene or oxidative stress, the direct correlation between γ-H2AX expression and telomere length can be lost. Senescence, however induced, leads to increased ROS production, leading to increased DSB foci within the cell [30]. Viruses, including EBV, induce γ-H2AX in infected cells [31]. Herpes virus γ-HV68 infection in a murine model led to γ-H2AX induction, which in turn increased viral replication [31]. Viruses induce cell-cycle arrest in order to generate a more favourable environment for replication. A direct effect of HCV on γ-H2AX expression in T cells is feasible, but was not investigated.

Chronic exposure of cells to IFN-β, but not IFN-α, led to irreversible p53-dependent cell-cycle arrest [32], whereby fibroblasts exposed to IFN-β for 6 days developed γ-H2AX expression, accumulation of mitochondrial-derived ROS and failure of proliferation. Perhaps the failure to demonstrate a stronger correlation between γ-H2AX and telomere length in patients with chronic HCV infection relates to chronic exposure of lymphocytes to IFN-α and subsequent expression of γ-H2AX. However, γ-H2AX + cells have increased expression of IFN-AR1, normally negatively regulated by IFN-α, which would suggest that these cells have not been stimulated through this pathway in vivo.

In a previous study, the degree of DNA damage in circulating lymphocytes in HCV-related, HBV-related and alcohol-related cirrhosis [33] correlated with the Child-Pugh score. Why circulating lymphocytes demonstrate DNA damage in patients with cirrhosis is unclear. Although we have excluded the possibility that γ-H2AX positive cells do not react to a single HLA-A2 restricted HCV epitope, it is possible that they might react to other epitopes in a non-HLA-A2 restricted fashion. However, we believe this unlikely given that the cells also do not react with the typically immunodominant A2-restricted pp65 epitope for CMV. Several previous studies have postulated the role of a bystander effect induced by chronic cytokine secretion in response to chronic viral infection leading to telomerase inhibition in the general, rather than antigen-specific, T-lymphocyte population [34]. It is plausible that γ-H2AX positive cells represent a multi-specific memory cell population that has re-circulated through the chronically inflamed liver in the context of HCV infection. Higher proportions of γ-H2AX positive cells in the liver would support this possibility. However, other groups have demonstrated that HCV infection is associated with a failure of maturation of non-HCV specific cells. Lucas et al. demonstrated that CMV-specific CD8+ T lymphocytes in HCV had fewer surface markers of an advanced differentiation state compared to non-HCV infected subjects [35].

Chronic HCV infection modulates the response to IFN-α through pSTAT1. HCV-NS5A prevents phosphorylation and nuclear translocation of pSTAT1 [18]. HCV-transfection of HuH7 cells leads to enhanced pSTAT1 degradation [36]. The N-terminal portion of HCV-core binds to the C-terminal portion of STAT1, blocking both homo- and hetero-dimerisation, preventing its intracellular actions [17]. HCV core protein reduced pSTAT1 in circulating T lymphocytes but increased pSTAT1 in B-lymphocytes HCV [37]. These findings may explain in part the increased EC50 for IFN-α in HCV infection, but not the very significant pathway defects seen in γ-H2AX + CD8+ T cells.

The failure to respond to IL-6 and IL-2 by phosphorylation of STAT1 and STAT5 respectively suggests a broader defect in senescent T lymphocytes in response to exogenous cytokine signals.

CD8+ γ-H2AX+ T lymphocytes have shortened telomeres, are highly differentiated, associated with severe fibrosis, are more frequent within the liver and although they have evidence of effector function (IFN-γ expression), do not activate Jak/Stat pathways in response to IFN-α, IL-2 or IL-6, perhaps explaining the failure of older patients and those with severe fibrosis to respond to treatment. Defining the cellular pathway linking advanced fibrosis, telomere shortening and failure to respond to IFN-α therapy could be important.

Financial support

MH was supported by a Wellcome Trust Clinical Research Training Fellowship. Consumable expenses were supported by the Addenbrooke’s Hepatology Endowment Fund and the Adenbrooke’s Liver Transplant Association.

Conflict of interest

The authors who have taken part in this study declare that they have nothing to disclose regarding funding or conflict of interest with respect to this manuscript.


Supplementary data associated with this article can be found, in the online version, at

Supplementary data

Supplementary Fig. 1:

Association of γ-H2AX expression on CD8+ T-lymphocytes with demographics and serostatus. Panels A–C. Correlations between γ-H2AX expression on CD8+ T-lymphocytes and serum ALT (Panel A), Bilirubin (Panel B) or prothrombin time (Panel C) in peripheral blood from HCV RNA+ subjects (n = 109). Panels D through I. Relationship between γ-H2AX expression on CD8+ T-lymphocytes and serostatus or demographics in the entire cohort (n = 161). Association between γ-H2AX expression on CD8+ T-lymphocytes and age (Panel D), anti-HBcoreserostatus (Panel E) or BMI (Panel F). Panel G–I. Association between γ-H2AX expression on CD8+ T-lymphocytes and CMV serostatus (n = 161).Analysis by Mann Whitney U test. Panel H. Circulating CD8+ T-lymphocyte subsets, defined by CD27 and CD57 expression, in CMV seronegative (n = 38) and seropositive subjects (n = 43). Panel F. γ-H2AX expression on CD8 + CD27- T-lymphocytes from seronegative (n = 38) and seropositive subjects (n = 43).

Supplementary Fig. 2:

Cell surface markers of activation and inhibitory receptors on γ-H2AX+ CD8+ lymphocytes. Cell surface expression of PD-1 (Panels A&B), CD38 (Panel C), CD69 (Panel D) and Tim3 (Panel E) on γ-H2AX-CD8+ (red lines) and γ-H2AX-CD8+ (blue lines) T-lymphocytes from subjects with viraemic HCV infection (n = 3).

Supplementary Fig. 3:

Antigen specificity of γ-H2AX+ CD8+ lymphocytes by class 1 pentamer analysis. Three HLA-A2 positive subjects with HCV viraemia and seropositive for CMV were studied for co-expression of γ-H2AX and pentamers for HCV-NS3 KLVALGINAV (upper panels) or CMV-pp65 NLVPMVATV (lower panels) on circulating CD8+ T-lymphocytes.

Supplementary Fig. 4:

Failure of CD8+ γ-H2AX+ cells to phosphorylate Stat1 does not relate to Stat1 expression or a failure to phosphorylate Tyk2 or Jak1. Panel A & B. Stat1 expression of CD8+ T-lymphocytes from subjects with viraemic HCV infection (n = 15); (A) example flow-cytometric plot demonstrating co-expression of γ-H2AX and whole Stat1; (B) stat1 expression in whole and γ-H2AX+ lymphocytes. Analysis by Wilcoxon signed rank test. Phosphorylation of Tyk2 (Panel C) and Jak1 (Panel D) on whole CD8+ and γ-H2AX+ CD8+ lymphocytes from viraemic HCV infected subjects (n = 9). Panels C&D demonstrate proportion of whole CD8+ and γ-H2AX+ CD8+ lymphocytes expressing phospho-Tyk2 (C) and phospho-Jak1 (D) after incubation with 1000 iu/ml IFN-α2b. Stats by Wilcoxon signed rank test.

Supplementary Materials and methods:


1. Missiha S.B., Ostrowski M., Heathcote E.J. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology. 2008;134:1699–1714. [PubMed]
2. Minola E., Prati D., Suter F., Maggiolo F., Caprioli F., Sonzogni A. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood. 2002;99:4588–4591. [PubMed]
3. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–832. [PubMed]
4. Pradat P., Voirin N., Tillmann H.L., Chevallier M., Trepo C. Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int. 2007;27:335–339. [PubMed]
5. Aikata H., Takaishi H., Kawakami Y., Takahashi S., Kitamoto M., Nakanishi T. Telomere reduction in human liver tissues with age and chronic inflammation. Exp Cell Res. 2000;256:578–582. [PubMed]
6. Grubeck-Loebenstein B., Wick G. The aging of the immune system. Adv Immunol. 2002;80:243–284. [PubMed]
7. Deng Y., Chan S.S., Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer. 2008;8:450–458. [PubMed]
8. d’Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer. 2008;8:512–522. [PubMed]
9. Herbig U., Jobling W.A., Chen B.P., Chen D.J., Sedivy J.M. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a) Mol Cell. 2004;14:501–513. [PubMed]
10. d’Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426:194–198. [PubMed]
11. Hao L.Y., Strong M.A., Greider C.W. Phosphorylation of H2AX at short telomeres in T cells and fibroblasts. J Biol Chem. 2004;279:45148–45154. [PubMed]
12. Ben-Porath I., Weinberg R.A. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol. 2005;37:961–976. [PubMed]
13. Taniguchi T., Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol. 2001;2:378–386. [PubMed]
14. Lalle E., Calcaterra S., Horejsh D., Abbate I., D’Offizi G., Abdeddaim A. Ability of peripheral blood mononuclear cells to activate interferon response in vitro is predictive of virological response in HCV patients. J Biol Regul Homeost Agents. 2008;22:153–160. [PubMed]
15. Sarasin-Filipowicz M., Oakeley E.J., Duong F.H., Christen V., Terracciano L., Filipowicz W. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA. 2008;105:7034–7039. [PubMed]
16. Aceti A., Zechini B., Griggi T., Marangi M., Pasquazzi C., Quaranta G. Undetectable phospho-STAT1 in peripheral blood mononuclear cells from patients with chronic hepatitis C who do not respond to interferon-alpha therapy. Liver Int. 2005;25:987–993. [PubMed]
17. Lin W., Kim S.S., Yeung E., Kamegaya Y., Blackard J.T., Kim K.A. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol. 2006;80:9226–9235. [PubMed]
18. Gong G.Z., Cao J., Jiang Y.F., Zhou Y., Liu B. Hepatitis C virus non-structural 5A abrogates signal transducer and activator of transcription-1 nuclear translocation induced by IFN-alpha through dephosphorylation. World J Gastroenterol. 2007;13:4080–4084. [PubMed]
19. Sebastian C., Herrero C., Serra M., Lloberas J., Blasco M.A., Celada A. Telomere shortening and oxidative stress in aged macrophages results in impaired STAT5a phosphorylation. J Immunol. 2009;183:2356–2364. [PubMed]
20. Hoare M., Gelson W.T., Das A., Fletcher J.M., Davies S.E., Curran M.D. CD4+ T-lymphocyte telomere length is related to fibrosis stage, clinical outcome and treatment response in chronic hepatitis C virus infection. J Hepatol. 2010;53:252–260. [PubMed]
21. Appay V., Dunbar P.R., Callan M., Klenerman P., Gillespie G.M., Papagno L. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8:379–385. [PubMed]
22. Northfield J.W., Kasprowicz V., Lucas M., Kersting N., Bengsch B., Kim A. CD161 expression on hepatitis C virus-specific CD8+ T cells suggests a distinct pathway of T cell differentiation. Hepatology. 2008;47:396–406. [PubMed]
23. Semmo N., Day C.L., Ward S.M., Lucas M., Harcourt G., Loughry A. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology. 2005;41:1019–1028. [PubMed]
24. Pugnale P., Pazienza V., Guilloux K., Negro F. Hepatitis delta virus inhibits alpha interferon signaling. Hepatology. 2009;49:398–406. [PubMed]
25. Pfeffer L.M., Basu L., Pfeffer S.R., Yang C.H., Murti A., Russell-Harde D. The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action. J Biol Chem. 1997;272:11002–11005. [PubMed]
26. Cytokines Gao.B. STATs and liver disease. Cell Mol Immunol. 2005;2:92–100. [PubMed]
27. Domanski P., Colamonici O.R. The type-I interferon receptor. The long and short of it. Cytokine Growth Factor Rev. 1996;7:143–151. [PubMed]
28. Sottini A., Ghidini C., Serana F., Chiarini M., Valotti M., Badolato R. Decreased type I interferon receptor-soluble isoform in antiretroviral-treated HIV-positive children. J Interferon Cytokine Res. 2008;28:181–189. [PubMed]
29. Takai H., Smogorzewska A., de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol. 2003;13:1549–1556. [PubMed]
30. Passos J.F., Nelson G., Wang C., Richter T., Simillion C., Proctor C.J. Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol Syst Biol. 2010;6:347. [PubMed]
31. Tarakanova V.L., Leung-Pineda V., Hwang S., Yang C.W., Matatall K., Basson M. Gamma-herpesvirus kinase actively initiates a DNA damage response by inducing phosphorylation of H2AX to foster viral replication. Cell Host Microbe. 2007;1:275–286. [PubMed]
32. Moiseeva O., Mallette F.A., Mukhopadhyay U.K., Moores A., Ferbeyre G. DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. Mol Biol Cell. 2006;17:1583–1592. [PubMed]
33. Grossi S., Sumberaz A., Gosmar M., Mattioli F., Testino G., Martelli A. DNA damage in peripheral blood lymphocytes of patients with cirrhosis related to alcohol abuse or to hepatitis B and C viruses. Eur J Gastroenterol Hepatol. 2008;20:22–25. [PubMed]
34. Fletcher J.M., Vukmanovic-Stejic M., Dunne P.J., Birch K.E., Cook J.E., Jackson S.E. Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion. J Immunol. 2005;175:8218–8225. [PubMed]
35. Lucas M., Vargas-Cuero A.L., Lauer G.M., Barnes E., Willberg C.B., Semmo N. Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. J Immunol. 2004;172:1744–1753. [PubMed]
36. Lin W., Choe W.H., Hiasa Y., Kamegaya Y., Blackard J.T., Schmidt E.V. Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology. 2005;128:1034–1041. [PubMed]
37. Yao Z.Q., Prayther D., Trabue C., Dong Z.P., Moorman J. Differential regulation of SOCS-1 signalling in B and T lymphocytes by hepatitis C virus core protein. Immunology. 2008;125:197–207. [PubMed]